



Marshfield Medical Center

## 2019 Inpatient Cumulative Antibigram

Contact Dr. Thomas Novicki or Dr. Thomas Fritsche at ext. 16300 (715-221-6300) for additional information regarding this report. Contact the Marshfield Clinic Pharmacy Drug Information Service at ext. 19800 (715-221-9800) for dosing and other drug information.

% Susceptible	<i>Enterobacter cloacae</i>	<i>Escherichia coli</i>	<i>Haemophilus Influenzae (IP/OP)</i>	<i>Klebsiella pneumoniae</i>	<i>Klebsiella (Enterobacter) aerogenes</i>	<i>Klebsiella oxytoca</i>	<i>Proteus mirabilis</i>
Maximum # Tested	51	504	-	109	25	44	61
Amikacin	100%	100%	-	100%	100%	100%	100%
Gentamicin	96%	94%	-	99%	100%	98%	87%
Tobramycin	96%	96%	-	99%	100%	98%	90%
Ampicillin	0%	56%	63%	0%	0%	0%	0%
Ampicillin/ Sulbactam	24%	65%	-	86%	44%	36%	98%
Piperacillin/ Tazobactam	82%	98%	-	96%	84%	86%	100%
Aztreonam	76%	94%	-	98%	80%	89%	100%
Cefazolin	0%	56%	-	82%	0%	5%	0%
Ceftazidime	76%	94%	-	96%	80%	98%	100%
Ceftriaxone	69%	92%	-	98%	76%	89%	100%
Cefepime	96%	98%	-	99%	100%	100%	100%
Meropenem	100%	100%	-	99%	100%	100%	100%
Ciprofloxacin	96%	82%	-	95%	100%	100%	77%
Levofloxacin	96%	83%	-	97%	100%	100%	79%
Tetracycline	90%	79%	-	91%	92%	95%	0%
Minocycline	92%	91%	-	90%	96%	98%	0%
Nitrofurantoin	67%	98%	-	86%	93%	95%	0%
Trimethoprim/ Sulphamethoxazole	100%	83%	-	94%	100%	98%	84%

IP/OP, combined inpatient and outpatient data.

% Susceptible	<i>Pseudomonas aeruginosa</i>	<i>Serratia marcescens</i>	<i>Stenotrophomonas maltophilia (IP/OP)</i>
Maximum # Tested	165	31	28
Amikacin	98%	100%	-
Gentamicin	96%	100%	-
Tobramycin	98%	97%	-
Ampicillin	0%	0%	-
Ampicillin/ Sulbactam	0%	23%	-
Piperacillin/ Tazobactam	93%	100%	-
Aztreonam	82%	100%	-
Cefazolin	0%	0%	-
Ceftazidime	91%	100%	72%
Ceftriaxone	0%	94%	-
Cefepime	95%	100%	-
Meropenem	96%	100%	-
Ciprofloxacin	87%	94%	-
Levofloxacin	87%	97%	93%
Tetracycline	0%	16%	-
Minocycline	0%	81%	100%
Nitrofurantoin	0%	0%	-
Trimethoprim/ Sulphamethoxazole	0%	100%	100%

IP/OP, combined inpatient and outpatient data.

% Susceptible	<i>Enterococcus faecalis</i>	<i>Enterococcus faecium</i>	<i>Staphylococcus aureus*</i>	<i>Staphylococcus epidermidis*</i>	<i>Streptococcus anginosus grp</i>	<i>Streptococcus pneumoniae (IP/OP)</i>
Maximum # Tested	176	32	423	171	39	33
Ampicillin	100%	31%	-	-	-	-
Penicillin	87%	13%	21%	10%	95%	-
Penicillin (Oral)	-	-	-	-	-	67%
Penicillin(meningitis)	-	-	-	-	-	67%
Penicillin(nonmeningitis)	-	-	-	-	-	97%
Oxacillin	-	-	63%	23%	-	-
Ceftaroline	-	-	100%	-	-	-
Ceftriaxone	-	-	-	-	100%	-
Ceftriaxone (meningitis)	-	-	-	-	-	88%
Ceftriaxone (nonmeningitis)	-	-	-	-	-	97%
Cefepime	-	-	-	-	100%	94%
Meropenem	-	-	-	-	100%	85%
Clindamycin	-	-	73%	47%	90%	88%
Erythromycin	-	-	54%	2%	77%	70%
Daptomycin	100%	100%	100%	100%	100%	-
Levofloxacin	74%	15%	70%	41%	95%	100%
Linezolid	100%	97%	100%	100%	100%	100%
Nitrofurantoin	100%	62%	96%	98%	-	-
Tetracycline	27%	25%	86%	85%	77%	85%
Trimethoprim/ Sulphamethoxazole	-	-	99%	-	-	70%
Vancomycin	100%	47%	100%	100%	100%	100%

\* Staphylococcal susceptibility to oxacillin predicts susceptibility to all anti-staphylococcal penicillins, cephalosporins, carbapenems, and beta lactam/ beta lactamase inhibitor combination drugs.

IP/OP, combined inpatient and outpatient data.